Independent Licensed Clinicians - contracted through affiliated professional entities including OpenLoop Health and CareGLP Affiliated P.C.s, according to MEDVi's published footer disclosures - review your health information and make the prescribing decision
Your main challenge is insurance coverage, which some plans restrict to higher BMIs
It is not intended for human consumption, medical use, diagnostic use, therapeutic use, weight-loss use, appetite-control use, glucose-management use, diabetes treatment use, obesity treatment use, supplement use, injection use, or the treatment, prevention, or diagnosis of any disease
Altendorfer, B
Gastrointestinal side effects are among the most common reasons people find these medications hard to tolerate, especially in the first weeks and while the dose is being increased (Drucker, 2024)
A 30-week dose of GLP-1 results in a 3.3 percent loss of weight and a drop in blood glucose A1C of 0.32 percentage points, changes that closely match clinical trial results